Month 2 Culture Status and Treatment Duration as Predictors of Tuberculosis Relapse Risk in a Meta-Regression Model

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Wallis, Robert S ^a   Wang, Cunshan ^a   Meyer, Daniel ^a   Thomas, Neal ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ARTICLE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; META REGRESSION MODEL; PREDICTION; RECURRENCE RISK; RISK ASSESSMENT; SPUTUM CULTURE; SPUTUM EXAMINATION; TREATMENT DURATION;

FOLLOW-UP STUDIES; HUMANS; META-ANALYSIS AS TOPIC; MICROBIOLOGICAL TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; PROGNOSIS; PYRAZINAMIDE; RECURRENCE; REGRESSION ANALYSIS; RIFAMPIN; RISK FACTORS; SPUTUM; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84881114100     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071116     Document Type: Article

References (20)

1. Wallis RS, (2013) Sustainable tuberculosis drug development. Clin Infect Dis 56: 106-113.
2. Wallis RS, Wang C, Doherty TM, Onyebujoh P, Vahedi M, et al. (2010) Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 10: 68-69.
3. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
4. Fox W, Ellard GA, Mitchison DA, (1999) Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3: S231-S279.
5. Hong Kong Chest Service-British Medical Research Council (1978) Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report. Am Rev Respir Dis 118: 219-228.
6. Okwera A, Johnson JL, Luzze H, Nsubuga P, Kayanja H, et al. (2006) Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala. Int J Tuberc Lung Dis 10: 39-44.
7. SAS Institute (2008) SAS/STAT User's Guide. Cary: SAS Institute.
8. Lunn D, Spiegelhalter D, Thomas A, Best N, (2013) The BUGS project: Evolution, critique and future directions. Stat Med 28: 3049-3082.
9. Mitchison DA, (1993) Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months [letter]. Am Rev Respir Dis 147: 1062-1063.
10. Mac Kenzie WR, Heilig CM, Bozeman L, Johnson JL, Muzanye G, et al. (2011) Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa. PLoS One 6: e18358.
11. Wang JY, Wang JT, Tsai TH, Hsu CL, Yu CJ, et al. (2010) Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int J Tuberc Lung Dis 14: 65-71.
12. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, et al. (2009) Substitution of Moxifloxacin for Isoniazid During Intensive Phase Treatment of Pulmonary Tuberculosis. Am J Respir Crit Care Med 180: 273-80.
13. Conde MB, Efron A, Loredo C, De Souza GR, Graca NP, et al. (2009) Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373: 1183-1189.
14. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, et al. (2008) A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 12: 128-138.
15. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M et al. (2006) Moxifloxacin versus Ethambutol in the First Two Months of Treatment for Pulmonary Tuberculosis. Am J Respir Crit Care Med.
16. Jindani A, Hatherill M, Charalambous S, Mungofa S, Zizhou S et al. (2013) A multicentre randomized clinical trial to evaluate high-dose rifapentine with a quinolone for treatment of pulmonary TB: The RIFAQUIN trial. Conference on Retroviruses and Opportunistic Infection 20. Abstract 147-LB.
17. Nunn AJ, Phillips PP, Mitchison DA, (2010) Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis 14: 241-242.
18. Wang JY, Lee LN, Lai HC, Hsu HL, Liaw YS, et al. (2007) Prediction of the tuberculosis reinfection proportion from the local incidence. J Infect Dis 196: 281-288.
19. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, et al. (2001) HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 358: 1687-1693.
20. Crampin AC, Mwaungulu JN, Mwaungulu FD, Mwafulirwa DT, Munthali K, et al. (2010) Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS 24: 417-426.